Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo- and Active-controlled, Randomised, Double-blind, Dose-escalation Phase I Study of IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics With the Exploration on Its Pharmacodynamics and Efficacy

Next Previous
Search
Trial Profile

A Placebo- and Active-controlled, Randomised, Double-blind, Dose-escalation Phase I Study of IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics With the Exploration on Its Pharmacodynamics and Efficacy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDG 16177 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Ildong Pharmaceutical

    • Most Recent Events

    • 09 Jul 2021 New trial record
    • 01 Jul 2021 According to an Ildong Pharmaceutical media release, the company has initiated this study and aims to complete this study by 2022.
    • 01 Jul 2021 According to an Ildong Pharmaceutical media release, on 28 June 2021, the company has received approval from the Federal Institute for Drugs and Medical Devices (BfArM) of German regulatory authority for this study. Based on this approval, the company will immediately commence Phase 1 study in Berlin, Germany.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top